• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Aurobindo Pharma Ltd has announced that the company has received approval from the US Food and Drug Administration (USFDA) for Amlodipine Besylate tablets 2.5 mg, 5 mg & 10 mg. This is the Hyderabad-based pharma major’s fifth anti-hypertensive approval from the USFDA. Amlodipine Besylate tablets 2.5 mg, 5 mg & 10 mg are the generic equivalent of Pfizer’s Norvasc. The tablets are indicated for the treatment of hypertension. The brand product has approxim ately annual sales of $2.8 billion. – Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Aurobindo gets FDA nod

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line